AHCOHealthcare · Medical DevicesThe 7 Wall Street analysts covering AdaptHealth Corp. hold a median 12-month price target of $10 — +65.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores AdaptHealth Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (20): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AHCO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +65.0% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $15 → $8.00 |
| 6 Aug 2026 | UBS | Maintains | Buy | $14 → $10 |
| 5 Aug 2026 | Truist Securities | Maintains | Buy | $14 → $9.00 |
| 21 July 2026 | Jefferies | Upgrade | Buy | — |
| 21 July 2026 | Jefferies | Upgrade | Buy | $11 → $13 |
| 6 July 2026 | Baird | Maintains | Outperform | — |
| 6 July 2026 | Baird | Maintains | Outperform | $18 → $15 |
| 11 May 2026 | RBC Capital | Maintains | Outperform | — |
| 6 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 May 2026 | UBS | Maintains | Buy | — |
| 13 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 26 Feb 2026 | Leerink Partners | Maintains | Outperform | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 12 May 2025 | Truist Securities | Maintains | Buy | — |
| 8 May 2025 | RBC Capital | Maintains | Outperform | — |
| 27 Feb 2025 | Baird | Maintains | Outperform | — |
| 26 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 26 Feb 2025 | RBC Capital | Maintains | Outperform | — |
| 26 Feb 2025 | Truist Securities | Maintains | Buy | — |
| 13 Feb 2025 | UBS | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AHCO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, AdaptHealth Corp. returned −36.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 43% of US stocks
Cheaper than 91% of US stocks
Cheaper than 83% of US stocks
Cheaper than 53% of US stocks
Higher than 58% of US stocks
Higher than 31% of US stocks
Higher than 3% of US stocks
Higher than 47% of US stocks
Higher than 22% of US stocks
Higher than 33% of US stocks
Higher than 60% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AdaptHealth Corp. has a market value of $808.5M and an enterprise value of $2.8B.
Revenue in the twelve months to 30 June 2026: $3.3B. The latest quarter grew 12.7% year on year.
Net income over the same four quarters: −$223.4M, a −6.9% net margin.
Diluted earnings per share, trailing twelve months: $−1.71.
Free cash flow in the twelve months to 30 June 2026: $97.7M.
Trailing P/E: 16.6×; forward P/E: −47.3× — the forward figure prices analyst consensus estimates, not reported earnings.
AdaptHealth Corp. employs 10,900 people — $299K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AdaptHealth Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
AdaptHealth Corp. announced it will participate in upcoming investor conferences, including the 2026 Jefferies Healthcare Services and Technology Conference in Nashville on Monday, September 14, 2026.
Why it matters — A AdaptHealth watcher would care because investor conference participation gives the company a public platform to present its healthcare-at-home business to investors.
AdaptHealth Corp. announced that its Board of Directors has appointed Harriss T. Currie as Chief Financial Officer, effective September 9, 2026. Currie will take over CFO responsibilities from Jason Clemens, who will assist with the transition.
Why it matters — A change in CFO leadership is significant for AdaptHealth watchers as it affects the company's financial management and leadership during the transition period.
Cathay Capital announced the launch of ReDream Brands, a new direct-to-consumer sleep health platform that combines four brands—cpap.com, The CPAP Shop, Lofta, and sleeping.com—to serve the cash-pay obstructive sleep apnea market across North America.
Why it matters — AHCO operates in the same sleep and CPAP space, so a consolidated direct-to-consumer platform could intensify competition in the cash-pay OSA market.
A national class action law firm, Edelson Lechtzin LLP, has launched an investigation into data privacy claims arising from a data breach at AdaptHealth Corp. The firm is examining exposure of personal information tied to the breach.
Why it matters — The investigation signals potential legal and regulatory exposure for AdaptHealth related to the handling of customer personal data.
AdaptHealth Corp. reported second-quarter 2026 revenue of $740.3 million, below the roughly $847–$849 million consensus, and a GAAP loss of $0.99 per share versus expectations of approximately $0.15. Following the miss, shares fell as much as 26%, and Levi & Korsinsky issued a securities investigation notice regarding the company.
Why it matters — AHCO watchers would care because the revenue and earnings shortfall triggered a significant share-price drop and an announced securities investigation tied to the results.
The 7 Wall Street analysts covering AdaptHealth Corp. have a median 12-month price target of $10, with estimates ranging from $7 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering AdaptHealth Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AdaptHealth Corp. 43 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, AdaptHealth Corp. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +65.0% from the last close, and Ticker Nerd's factor model ranks AdaptHealth Corp. 43 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AdaptHealth Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AHCO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $10 over the next 12 months.
AdaptHealth Corp. returned -36.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
AdaptHealth Corp. is a healthcare services company that provides home medical equipment, medical supplies, and related patient support services across the United States.
The most recent item we track (Business Wire, 11 Sept 2026): "AdaptHealth To Participate in Upcoming Investor Conferences". AdaptHealth Corp. announced it will participate in upcoming investor conferences, including the 2026 Jefferies Healthcare Services and Technology Conference in Nashville on Monday, September 14, 2026.
AdaptHealth Corp. is a healthcare services company that provides home medical equipment, medical supplies, and related patient support services across the United States. The company focuses on care delivered outside the hospital through offerings in sleep health, respiratory health, diabetes health, and wellness at home. Its products and services include sleep therapy equipment, oxygen and ventilation systems, continuous glucose monitors, insulin pumps, and a broad range of durable medical equipment used in chronic and post-acute care. AdaptHealth works with Medicare, Medicaid, and commercial insurance patients, serving individuals who need recurring medical support in the home. The company plays an important role in the healthcare-at-home market by helping patients manage ongoing conditions with equipment, supplies, and service coordination tailored to home-based care.
CEO Ms. Suzanne M. Foster M.P.H. · 10,900 employees · United States · https://adapthealth.com
